参考文献
［1］Lee A, Moon BI, Kim TH. Pathogenic variant breast cancer: treatment and prevention strategies［J］. Ann Lab Med, 2020, 40(2): 114—121.
［2］Dieli-Conwright CM, Courneya KS, Demark-Wahnefried W, et al. Aerobic and resistance exercise improves physical fitness, bone health, and quality of life in overweight and obese breast cancer survivors: a randomized controlled trial［J］. Breast Cancer Res, 2018,20(1): 124.
［3］Mehta LS, Watson KE, Barac A, et al. Cardiovascular disease and breast cancer: where these entities intersect: A Scientific Statement From the American Heart Association［J］.Circulation, 2018, 137(8): e30—e66.
［4］Rojas K, Stuckey A. Breast cancer epidemiology and risk factors［J］. Clin Obstet Gynecol,2016, 59(4): 651—672.
［5］Gradishar WJ, Anderson BO, Abraham J, et al. Breast Cancer, Version 3. 2020, NCCN Clinical Practice Guidelines in Oncology［J］. J Natl Compr Canc Netw, 2020, 18(4):452—478.
［6］Shoemaker ML, White MC, Wu M, et al. Differences in breast cancer incidence among young women aged 20—49 years by stage and tumor characteristics, age, race, and ethnicity, 2004—2013［J］. Breast Cancer Res Treat, 2018, 169(3): 595—606.
［7］Erić I, Petek Erić A, Kristek J, et al. Breast cancer in young women: pathologic and immunohistochemical features［J］. Acta Clin Croat, 2018, 57(3): 497—502.
［8］Hartmann LC, Sellers TA, Frost MH, et al. Benign breast disease and the risk of breast cancer［J］. N Engl J Med, 2005, 353(3): 229—237.
［9］Lee J, Kim S, Kang E, et al. Influence of the Angelina Jolie Announcement and Insurance Reimbursement on Practice Patterns for Hereditary Breast Cancer［J］. J Breast Cancer,2017, 20(2): 203—207.
［10］Fountzilas C, Kaklamani VG. Multi-gene panel testing in breast cancer management［J］.Cancer Treat Res, 2018, 173: 121—140.
［11］Tsai M, Lo S, Audeh W, et al. Association of 70-gene signature assay findings with physicians’ treatment guidance for patients with early breast cancer classified as intermediate risk by the 21-gene assay［J］. JAMA Oncol, 2018, 4(1): e173470.
［12］Poulet G, Massias J, Taly V. Liquid biopsy: general concepts［J］. Acta Cytol, 2019, 63(6):449—455.(https://www.daowen.com)
［13］Alix-Panabières C, Pantel K. Clinical applications of circulating tumor cells and circulating tumor DNA as liquid biopsy［J］. Cancer Discov, 2016, 6(5): 479—491.
［14］Onidani K, Shoji H, Kakizaki T, et al. Monitoring of cancer patients via next-generation sequencing of patient-derived circulating tumor cells and tumor DNA［J］. Cancer Sci,2019, 110(8): 2590—2599.
［15］Nurgalieva Z, Liu CC, Du XL. Chemotherapy use and risk of bone marrow suppression in a large population-based cohort of older women with breast and ovarian cancer［J］. Med Oncol, 2011, 28(3): 716—725.
［16］Iżycki D, Niezgoda A, Kaźmierczak M, et al. Chemotherapy-induced peripheral neuropathy -epidemiology and pathogenesis［J］. Ginekol Pol, 2016, 87(4): 293—299.
［17］Andreyev J, Ross P, Donnellan C, et al. Guidance on the management of diarrhoea during cancer chemotherapy［J］. Lancet Oncol, 2014, 15(10): e447—e460.
［18］Toygar İ, Yeşilbalkan ÖU, Kürkütlü M, et al. Complementary and alternative medicines used by cancer patients to cope with chemotherapy-induced constipation［J］. Complement Ther Clin Pract, 2020, 39: 101108.
［19］Braal CL, Jongbloed EM, Wilting SM, et al. Inhibiting CDK4/6 in breast cancer with palbociclib, ribociclib, and abemaciclib: similarities and differences［J］. Drugs, 2021,81(3): 317—331.
［20］Rinnerthaler G, Gampenrieder SP, Greil R. HER2 directed antibody-drug-conjugates beyond T—DM1 in breast cancer［J］. Int J Mol Sci, 2019, 20(5).
［21］Slade D. PARP and PARG inhibitors in cancer treatment［J］. Genes Dev, 2020, 34(5—6):360—394.
［22］Michel L, Schadendorf D, Rassaf T. Oncocardiology: new challenges, new opportunities［J］. Herz, 2020, 45(7): 619—625.
［23］Colwell AS, Taylor EM. Recent Advances in Implant-Based Breast Reconstruction［J］.Plast Reconstr Surg, 2020, 145(2): 421e—432e.
［24］Kwakman JJM, Elshot YS, Punt CJA, et al. Management of cytotoxic chemotherapy-induced hand-foot syndrome［J］. Oncol Rev, 2020, 14(1): 442.